Stay updated on Asciminib Combo with Imatinib in CML-CP Clinical Trial

Sign up to get notified when there's something new on the Asciminib Combo with Imatinib in CML-CP Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Asciminib Combo with Imatinib in CML-CP Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    New navigation items and help sections were added to the Study Details page, including How to Read a Study Record, Common Questions, How to Join a Study, and an updated Intervention/Treatment section. The previous label 'Intervention / Treatment' was replaced with 'Intervention/Treatment', and the site revision note updated to Revision: v3.6.0.
    Difference
    0.3%
    Check dated 2026-06-15T05:43:53.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page's revision label now shows v3.5.5, replacing v3.5.4. This reflects a minor update to the page's revision metadata rather than content changes.
    Difference
    0.0%
    Check dated 2026-06-08T03:48:09.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    The page’s revision label has been updated from v3.5.3 to v3.5.4, indicating a minor update to the documentation/versioning of the study page. This reflects an administrative update rather than any change to the trial data or details.
    Difference
    0.0%
    Check dated 2026-05-17T09:18:30.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Taoyuan District, Taiwan, 33305 was replaced with Taoyuan, Taiwan, 33305 in the Locations section. This updates the listed site to reflect the correct municipality.
    Difference
    0.0%
    Check dated 2026-05-03T01:22:12.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The study record has been updated to reflect an additional **asciminib 80 mg single-agent cohort (ASAC)** added after the primary analysis, alongside the ongoing randomized add-on/switch/continue arms. Corresponding **primary/secondary outcome measure definitions** and related endpoint timing (e.g., **MR4.5 rates at 48 and 96 weeks** and related analyses) were also updated to include this single-agent evaluation.
    Difference
    4%
    Check dated 2026-04-25T18:44:25.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    Revision added: v3.5.2. Revision removed: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-18T13:34:37.000Z thumbnail image

Stay in the know with updates to Asciminib Combo with Imatinib in CML-CP Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Asciminib Combo with Imatinib in CML-CP Clinical Trial page.